# EMPAGLIFLOZIN AND LINAGLIPTIN
> **ANDA212264** · Abbreviated New Drug Application (Generic) · Sponsor: PRINSTON PHARMA INC · Approved 2022-01-20
## Drug
- **FDA Application Number:** ANDA212264
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** EMPAGLIFLOZIN AND LINAGLIPTIN
- **Generic name:** Empagliflozin
- **Active ingredients:** EMPAGLIFLOZIN; LINAGLIPTIN
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** PRINSTON PHARMA INC
- **First approval:** 2022-01-20
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212264)
---
*MORVS · CC0 1.0*